Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)-Reference-Cited by-同舟云学术

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)

Published:2019-07-16 Issue:6 Volume:12 Page:611-619
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Wells Jane R.^ORCID,Gater Adam,Marshall Chris,Tritton Theo,Vashi Parth,Kessabi Sophia

Funder

Bayer Corporation

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40271-019-00374-x.pdf

Reference29 articles.

1. Flood E, Pocoski J, Michaels LA, Bell JA, Valluri S, Sasanè R. Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models. Eur J Haematol. 2014;93(Suppl 75):9–18.

2. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20(4):459–63.

3. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447–56.

4. National Hemophilia Foundation. MASAC Recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). MASAC Document #241. Hemophilia Foundation; 2016. https://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf : National. Accessed 10 Apr 2019.

5. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adher. 2017;11:1677.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments;Journal of Patient-Reported Outcomes;2024-04-20

3. Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs;TH Open;2024-04

4. A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board;The Journal of Haemophilia Practice;2024-01-01

5. Quality of life, self-reported outcomes and impact of education among people with moderate and severe hemophilia A: An integrated perspective from a Latin American country;PLOS ONE;2023-07-06